E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区E2蛋白含有中和性抗表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受免疫性表位特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将制剂从宿主撤离，宿主仍能保持对存在于耐受原上的原性表位的特异性耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导生中和性抗。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从离，仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免剂从宿主撤离，宿主仍能保持对存在于耐受原上的免原性表位的特异性免耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，抑制剂从宿主撤离，宿主仍能保持对存在于耐受原上的原性表位的特异性耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有中和性抗原表位，能诱导机体产生中和性抗体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从主，主仍能保持对存在于耐受原上的免疫原性表位的特异性免疫耐受。

E2 protein, including hypervariable region 1 (HVR1) in the N-terminal region, contains some epitopes that can induce neutralizing antibodies.

括高变区的E2蛋白含有表位，能诱导机体产生体。

After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen.

在致耐受方案后，将免疫抑制剂从宿主撤离，宿主仍能保持对存在于耐受上的免疫表位的特异免疫耐受。